We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma
GastroenterologydMMRgastroesophageal adenocarcinoma

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY|Jun 19, 2026

This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
Diabetes & Endocrinologyimmunotherapy
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Long-Term Safety

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

By MedXY|Jun 19, 2026

Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET
newsgestational trophoblastic tumorsimmunotherapy

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

By MedXY|Aug 18, 2026

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
Hematology-Oncologyfirst-line treatmentimmunotherapy

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY|Jun 7, 2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma
newsimmune checkpoint inhibitorsrecurrent vulvar cancer

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY|Aug 18, 2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer
newsBMIhead and neck cancer

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

By MedXY|May 20, 2026

In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes
Clinical UpdatesBeta-cell Protectionclinical research

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

By MedXY|May 20, 2026

Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer
newshead and neck cancerimmunotherapy

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

By MedXY|Apr 27, 2026

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Gastroenterologyablation therapyhepatocellular carcinoma

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

By MedXY|Apr 14, 2026

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge
newsimmunotherapyNon-Small Cell Lung Cancer

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

By MedXY|Apr 14, 2026

A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
newscervical cancerEndometrial Cancer

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

By MedXY|Apr 6, 2026

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma
Clinical UpdatesBoHV-1immunotherapy

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

By MedXY|Apr 5, 2026

This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer
Clinical UpdatesimmunotherapyNSCLC

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

By MedXY|Apr 2, 2026

This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data
Clinical Updatescamrelizumabimmunotherapy

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

By MedXY|Mar 20, 2026

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results
Clinical UpdatesAlloHSCTGVHD

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

By MedXY|Mar 20, 2026

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis
Clinical Updatesdeep learninghepatocellular carcinoma

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

By MedXY|Mar 15, 2026

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion
Hematology-OncologyBCMABispecific Antibodies

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY|Mar 13, 2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Gastroenterologyhepatocellular carcinomaimmunotherapy

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

By MedXY|Mar 12, 2026

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial
Gastroenterologyhepatocellular carcinomaHIMALAYA Trial

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY|Mar 11, 2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY|Mar 9, 2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat

Prev
2 / 9
1234…9
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities